Macrophage Activation Syndrome as the Initial Manifestation of Systemic Lupus Erythematosus in a 7-Year-Old Girl – A Case Report.
Journal of Pediatric Nephrology,
Vol. 5 No. 1 (2017),
6 Khordad 2017
,
Page 1-4
https://doi.org/10.22037/jpn.v5i1.13776
Abstract
Macrophage activation syndrome (MAS) is a potentially fatal complication of several chronic rheumatic diseases. Although it occurs most commonly with systemic onset juvenile idiopathic arthritis (SoJIA), it may also occur in association with systemic lupus erythematosus (SLE), Kawasaki disease, and adult onset Still’s disease. It is usually triggered by infections or due to medication modification. Here we report a 7-year-old girl who presented simultaneously with features of MAS and SLE and responded with pulse methylprednisolone followed by oral prednisolone and pulse cyclophosphamide.
Keywords: Macrophage Activation Syndrome (MAS); Systemic Lupus Erythematosus (SLE); Child.
- Macrophage Activation Syndrome(MAS)
- Systemic Lupus Erythematosus (SLE).
How to Cite
References
Levy DM, Kamphuis S. Systemic lupus erythematosus in children and adolescents. PediatrClin North Am. 2012; 59:345-64.
Stichweha D, Arcea E, Pascual V. Update on pediatric systemic lupus erythematosus. CurrOpinRheumatol.2004; 16:577-87.
Grom AA, Passo M. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis. J Pediatr 1996; 129:630-32.
Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 2001; 85:421–26.
Stephan JL, Kone-Paut I, Galambrun C, Mouy R, Bad¬er-Meunier B, Prieur AM. Reactive haemophagocytic syndrome in children with inflammatory disorders: a retrospective study of 24 patients. Rheumatology 2001; 40:1285-92.
Avcin T, Tse SM, Schneider R, Ngan B, Silverman ED. Macrophage activation syndrome as the presenting man¬ifestation of rheumatic diseases in childhood. J Pediatr 2006; 148: 683–86.
Latino GA, Manlhiot C, Yeung RS, Chahal N, McCrindle BW. Macrophage activationsyndrome in the acute phase of Kawasaki disease.JPediatrHematolOncol 2010; 32:527-531.
Sterba G, Rodriguez C, Sifontes S, Vigilanza P. Mac-rophage activation syndrome due to methotrexate in a 12-year-old boy with dermatomyositis. J Rheumatol. 2004; 31:1014-15.
Rigante D, Capoluongo E, Bertoni B, Ansuini V, Chiaretti A, Piastra M, et al. First report of macrophage activation syndrome in hyperimmunoglobulinemia D with peri¬odic fever syndrome.Arthritis Rheum 2007; 56:658-61.
Rossi-Semerano L, Hermeziu B, Fabre M, Kone-Paut I. Macrophage activation syndrome revealing familial Med¬iterranean fever. Arthritis Care Res 2011; 63:780-83.
S. Vilaiyuk, N. Sirachainan, S. Wanitkun, K. Pirojsakul, and J.Vaewpanich, “Recurrent macrophage activation syndrome as the primary manifestation in systemic lupus erythematosus and the benefit of serial ferritinmeasurements: a case-based review,”ClinicalRheumatology.2013; 32(6): 899–904.
Carvalheiras G, Anjo D, Mendonca T, Vasconcelos C, Farinha F. Hemophagocytic syndrome as one of the main primary manifestations in acute systemic lupuserythematosus—case report and literature review. Lupus.2010; 19:756–61.
Janka GE. Hemophagocyticsyndromes.Blood Rev. 2007; 21:245–53.
Avcin T, Tse SM, Schneider R, Ngan B, Silverman ED. Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood.JPediatr. 2006;148:683–86.
Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Il-owite NT, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-on¬set systemic juvenile idiopathic arthritis.Arthritis Rheum.2007; 56:965-71.
Morales PM, Jimenez BF, Yanes P, Rios D, Godinez R. Bone marrow (BM) with reactive histiocytosis (RH), hemophagocytosis and storage histiocytes (SH) in sys¬temic lupus erythematosus . Arthritis Rheum 1992; 35Suppl: S239.
Parodi A, Davi S, Pringe AB, Pistorio A, Ruperto N, Mag¬ni Manzoni S, et al.. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multina¬tional multicenter study of thirty-eight patients. Arthritis Rheum 2009; 60:3388-99.
Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocyticlymphohistiocytosis. Pediatr Blood Cancer.2007; 48:124–31.
A. Zeft, R. Hollister, B. Lafleur, John Bohnsack.“Anakinra for systemicjuvenile arthritis: the rocky mountain experience,”Journal ofClinical Rheumatology.2009: 15,( 4) : 161–64.
P. A. Nigrovic, M. Mannion, F. H. M. Prince, Z Andrew, C E Rabinovich, M A J V Rossum.et al., “Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series,” Arthritis and Rheumatism, 2011; 63(2), pp:545–555.
- Abstract Viewed: 978 times
- PDF Downloaded: 438 times